Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 15

Results For "ICAR"

150 News Found

Firstsource Solutions launch Healthcare Cloud
Digitisation | September 12, 2021

Firstsource Solutions launch Healthcare Cloud

The platform revolutionizes how providers deliver financial services by radically simplifying the patient financial experience


Indigenous technology will help reduce dependence on imports: Dr Singh
Digitisation | September 03, 2021

Indigenous technology will help reduce dependence on imports: Dr Singh

Union Minister addresses the 13th CII Global MedTech Summit on the sunrise medical devices sector in India


Pear Therapeutics’ three FDA authorised prescriptions available at OptumRx
Digitisation | August 11, 2021

Pear Therapeutics’ three FDA authorised prescriptions available at OptumRx

OptumRx to make Pear’s three commercial Prescription Digital Therapeutics accessible to patients with Optum formulary access.


SPI Pharma partners Azelis Americas
Supply Chain | August 07, 2021

SPI Pharma partners Azelis Americas

In the agreement, Marcor, an Azelis Americas company, will distribute the SPI Pharma product lines in the United States, and Azelis Canada Pharma Division will be responsible for the Canadian marketplace


Biocon Q1FY22 revenue up 6% at Rs 1,808 Cr
News | July 23, 2021

Biocon Q1FY22 revenue up 6% at Rs 1,808 Cr

Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).


Balaxi Pharmaceuticals Q1 revenue increases by 12%
News | July 20, 2021

Balaxi Pharmaceuticals Q1 revenue increases by 12%

The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY


Balaxi records Q4 FY21 revenue of Rs. 53 Cr
News | May 22, 2021

Balaxi records Q4 FY21 revenue of Rs. 53 Cr

Drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday


Biosimilars performance below expectations for Biocon : ICICI Direct
Biotech | May 03, 2021

Biosimilars performance below expectations for Biocon : ICICI Direct

The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.


Hester to commercialize vaccines for animals
News | April 09, 2021

Hester to commercialize vaccines for animals

Both the vaccines have been extensively tested by IVRI for safety and potency and have been found to provide 100% protection


Vivimed Labs receives products approvals from Uzbekistan
News | March 09, 2021

Vivimed Labs receives products approvals from Uzbekistan

Vivimed strategy is to increase its share of Branded products in CIS Markets.